Drug intelligence / Profile preview

DB-3Y

Development stage: Preclinical
Lead developer: Direct Biologics
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems

Overview

DB-3Y is an investigational biologic therapy composed of extracellular vesicles (EVs) derived from bone marrow mesenchymal stem/stromal cells (bmMSCs). These EVs contain growth factors, cytokines, mRNA, and noncoding RNA (miRNA), and are being developed for their anti-inflammatory properties. DB-3Y is currently under clinical investigation for the treatment of medically refractory ulcerative colitis. The product is acellular and nonimmunogenic, aiming to leverage the beneficial effects of stem cell-derived messengers without introducing live cells. The developer and manufacturer is Direct Biologics[6].

Beyond the preview

Go deeper on DB-3Y.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DB-3Y.

Explore the full profile